DIA Biosimilars 2013

Kendle

Kendle Cutting Staff to Offset Drop in Sales

Thursday, February 25, 2010 01:45 PM

Kendle plans to reduce staffing levels in the coming months in response to decreased sales and customer demand.

More... »

Cenduit: Now with Patient Reminders

Kendle 3Q Revenues, Net Income Slide

Thursday, November 5, 2009 09:16 AM

Kendle, a global contract research organization, reported third quarter net income slipped to $8.8 million or $0.59 per diluted share for the third quarter of 2009, compared with net income of $9.4 million or $0.62 per diluted share for the third quarter of 2008.  

More... »

CRF Health – eCOA Forum

Kendle Reports 50% Income Drop, Suspends Guidance for 2009

Thursday, August 6, 2009 08:04 AM

Kendle’s net income was cut almost 50% in the second quarter 2009 with income dropping to $3.2 million, or $0.21 per diluted share, compared with net income of $6.3 million, or $0.42 per diluted share in Q2 2008. Net revenues for the quarter were $107.4 million, down from $127 million during the same period last year.

More... »

Encorium Acquisition Leads to CEO Move, COO Departure

Friday, July 24, 2009 11:39 AM

Wayne, Pa.-based contract research organization (CRO) Encorium Group has completed the sale of its U.S. business to Pierrel Research USA, a subsidiary of Italian CRO Pierrel SpA, for $2.7 million.

More... »

Kendle Opens New International Offices

Tuesday, June 16, 2009 07:32 AM

Cincinnati-based contract research organization (CRO) Kendle opened three new international offices--in Kuala Lumpur, Malaysia; Bangkok, Thailand; and Manila, Philippines.

More... »

CenterWatch Monthly June 2009

Friday, June 5, 2009 09:17 AM

U.S. Sites Rate Medpace, Kendle, ICON as Top CROs in 2009

More... »

Kendle Faces Questions about Pricing Pressures

Monday, May 11, 2009 07:00 AM

After warning investors two weeks ago that first quarter 2009 revenues would be significantly lower than expected, Cincinnati-based contract research organization (CRO) Kendle released its first quarter earnings late last week—reporting a 78% drop in profit compared with the same period last year.

More... »

Kendle Reports 78% Drop in Profits, Begins Cost-Saving Efforts

Thursday, May 7, 2009 07:00 AM

Cincinnati-based contract research organization (CRO) Kendle warned investors earlier this month that first quarter 2009 profits would be down, and down they are.

More... »

CROs See Brighter Future Despite Cancellations

Monday, May 4, 2009 08:00 AM

Contract research organizations (CROs) continue to feel the adverse effects of cancellations and negative foreign exchange, but their most recent earnings reports show some promise.

More... »

ICON, Kendle Finish Strong 2008 on Soft Side

Monday, March 2, 2009 08:00 AM

It was another quarter of ups and downs for the clinical trial industry as contract research organizations (CROs) struggled through project delays and customer hesitation brought on by the unstable economy. In spite of the challenges, however, two CROs—ICON and Kendle—finished the year on top.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs